Sign up
Pharma Capital

Oragenics raises $1.8 million to battle oral mucositis

Oragenics Inc CEO (NYSE American:OGEN) Alan Joslyn tells Proactive Investors the biopharmaceutical company recently raised US$1.8mln to further advance clinical programs in developing effective treatments for oral mucositis, a debilitating complication of cancer treatments.

Joslyn says oral mucositis affects about 6 million people worldwide.

 

View full OGEN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.